Lee Joanna S, Toktas Osman, Soran Atilla
Section of Breast Surgical Oncology, Division of Surgical Oncology, University of Pittsburgh Medical Center Magee-Womens Hospital, Pittsburgh, PA, USA.
Clin Med Insights Oncol. 2020 Sep 17;14:1179554920942440. doi: 10.1177/1179554920942440. eCollection 2020.
It is estimated that approximately 154000 women in the United States have stage IV breast cancer (BC). A subset of this group has metastatic disease at presentation, known as de novo stage IV disease. De novo stage IV BC accounts for approximately 6% of all BC diagnoses in the United States. Traditionally, stage IV BC patients are treated with primary systemic therapy with a palliative intent reserving possible locoregional treatment (LRT) as last resort. There has been a lot of interest in the role of LRT in de novo stage IV BC for the past decade with mixed conclusions. Although this review is not intended to be a comprehensive overview of all literature regarding this topic to date, we will review the recent findings in literature focusing on the studies with larger sample sizes to investigate the role of LRT in de novo stage IV BC.
据估计，美国约有154000名女性患有IV期乳腺癌（BC）。该群体中的一部分在初诊时就有转移性疾病，即所谓的新发IV期疾病。新发IV期BC约占美国所有BC诊断病例的6%。传统上，IV期BC患者接受以姑息为目的的一线全身治疗，将可能的局部区域治疗（LRT）作为最后手段。在过去十年中，人们对LRT在新发IV期BC中的作用非常感兴趣，但结论不一。尽管本综述并非旨在全面概述迄今为止关于该主题的所有文献，但我们将回顾文献中的最新发现，重点关注样本量较大的研究，以探讨LRT在新发IV期BC中的作用。
